BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single-center, open-label, exploratory study evaluating ifupinostat hydrochloride (BEBT-908) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with MEF2D rearrangement. The study will include patients with relapsed or refractory disease and patients who are in morphologic remission but still have measurable residual disease (MRD). The main purpose of the study is to evaluate the preliminary anti-leukemia activity of BEBT-908 in patients with relapsed or refractory disease and its ability to reduce or eliminate residual leukemia in patients with MRD-positive disease. The study will also assess the depth and duration of response, survival outcomes, subsequent treatment such as stem cell transplantation or CAR-T therapy, and the safety and tolerability of BEBT-908. Approximately 10 to 15 participants aged 14 to 75 years are planned to be enrolled. All participants will receive BEBT-908 by intravenous infusion at 18.5 mg/m² on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle for up to two cycles. Bone marrow morphology, flow cytometry MRD, and MEF2D fusion transcript levels will be evaluated during the study to assess treatment response.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent świadomie zgadza się na udział w badaniu i podpisuje formularz zgody.
- •Pacjent ma co najmniej 14 lat, ale nie więcej niż 75 lat.
- •U pacjenta zdiagnozowano ostrą białaczkę limfoblastyczną z komórek prekursorowych B.
- •Wcześniejsze badania wykazały obecność rearanżacji genu MEF2D, co potwierdzono podczas badań przesiewowych.
- •Choroba pacjenta jest nawrotowa lub oporna na leczenie lub pacjent jest w remisji, ale wciąż ma wykrywalną chorobę resztkową (MRD pozytywną).
- •Pacjent jest w ogólnie dobrym stanie zdrowia, pozwalającym na udział w badaniu (stan sprawności ECOG 0-2).
- •Przewidywana długość życia pacjenta to ponad 12 tygodni.
- •Wyniki podstawowych badań narządów (wątroby) mieszczą się w normie.
✗ Disqualifies
- •Brak danych o kryteriach wykluczenia w dostarczonym tekście.
Simplified criteria — AI translation
Trial details
- Minimum age
- 14 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The first affiliated hospital of soochow university
Suzhou, China
Trial contact
Suning Chen, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.